Thoracoscopic lobectomy is associated with superior compliance with adjuvant chemotherapy in lung cancer

Annals of Thoracic Surgery

Volumn 91, Issue 2, 2011, Pages 344-348

  Lee, Jin Gu ^a   Cho, Byoung Chul ^a   Bae, Mi Kyung ^a   Lee, Chang Young ^a   Park, In Kyu ^a   Kim, Dae Joon ^a   Chung, Kyung Young ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CELL COUNT; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CANCER; LUNG LOBECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE PAIN; PRIORITY JOURNAL; THORACOSCOPY; THORACOTOMY;

EID: 78751676231     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2010.09.031     Document Type: Article

References (14)

1. R. Arriagada, A. Dunant, and J.P. Pignon Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer J Clin Oncol 28 2010 35 42
2. T.L. Winton, R. Livingstan, and D. Johnson A prospective randomized trial of adjuvant vinorelbine (VNR) and cisplatin (CIS) in completely resected stage Ib and II non small cell lung cancer (NSCLC) Intergroup JBR10 N Engl J Med 352 2005 2589 2597
3. G.M. Strauss, J. Hernden, and M.A. Maddaus Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage Ib non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract] J Clin Oncol 22 2004 621s
4. G.M. Strauss, J.E. Hernden, and M.A. Maddaus Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups J Clin Oncol 26 2008 5043 5051
5. J. Douillard, R. Rosell, and M. Delena Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IBIIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial Lancet Oncol 7 2006 719 727
6. N. Alam, F.A. Shepherd, and T. Winton Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer An analysis of National Cancer Institute of Canada and Intergroup Trial JBR.10 and a review of the literature Lung Cancer 47 2005 385 394
7. N.R. Villamizar, M.D. Darrabie, and W.R. Burfeind Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy J Thorac Cardiovasc Surg 138 2009 419 425
8. S. Paul, N.K. Altorki, and S. Sheng Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database J Thorac Cardiovasc Surg 139 2010 366 378
9. D.G. Nicastri, J.P. Wisnivesky, and V.R. Litle Thoracoscopic lobectomy: report on safety, discharge independence, pain, and chemotherapy tolerance J Thorac Cardiovasc Surg 135 2008 642 647
10. R.P. Petersen, D. Pham, and W.R. Burfeind Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer Ann Thorac Surg 83 2007 1245 1250
11. C.F. Mountain Revision of the international system for staging lung cancer Chest 111 1997 1710 1717
12. C.S. Ng, R.L. Whelan, and A.M. Lacy Is minimal access surgery for cancer associated with immunologic benefits? World J Surg 29 2005 975 981
13. C.S. Ng, T.W. Lee, and S. Wan Thoracotomy is associated with significantly more profound suppression in lymphocytes and natural killer cells than video assisted thoracic surgery following major lung resections for cancer J Invest Surg 18 2005 81 88
14. H.A. Leaver, S.R. Craig, and P.L. Yap Lymphocyte responses following open and minimally invasive thoracic surgery Eur J Clin Invest 30 2000 230 238